Litcius/Paper detail

Anti-membrane Antibodies Persist at Least One Year and Discriminate Between Past Coronavirus Disease 2019 Infection and Vaccination

Maya F. Amjadi, Ryan R. Adyniec, Srishti Gupta, S. Janna Bashar, Aisha M. Mergaert, Katarina M. Braun, Gage K. Moreno, David H. O’Connor, Thomas C. Friedrich, Nasia Safdar, Sara S. McCoy, Miriam A. Shelef

2022The Journal of Infectious Diseases18 citationsDOIOpen Access PDF

Abstract

BACKGROUND: The consequences of past coronavirus disease 2019 (COVID-19) infection for personal and population health are emerging, but accurately identifying distant infection is a challenge. Anti-spike antibodies rise after both vaccination and infection and anti-nucleocapsid antibodies rapidly decline. METHODS: We evaluated anti-membrane antibodies in COVID-19 naive, vaccinated, and convalescent subjects to determine if they persist and accurately detect distant infection. RESULTS: We found that anti-membrane antibodies persist for at least 1 year and are a sensitive and specific marker of past COVID-19 infection. CONCLUSIONS: Thus, anti-membrane and anti-spike antibodies together can differentiate between COVID-19 convalescent, vaccinated, and naive states to advance public health and research.

Topics & Concepts

AntibodyVaccinationCoronavirusImmunologyVirologyCoronavirus disease 2019 (COVID-19)DiseaseSerologyPopulationMedicineBiologyInfectious disease (medical specialty)PathologyEnvironmental healthSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19Monoclonal and Polyclonal Antibodies Research